← All trials
NCT07262008
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2026
- Primary completion
- Feb 1, 2027
- Completion date
- Sep 1, 2028
- First posted
- Dec 3, 2025
- Last posted
- Dec 10, 2025
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of TorontoLead sponsor
- Canadian Institutes of Health Research (CIHR)Collaborator
- University of TorontoCollaborator
- Unity Health TorontoCollaborator
- University of TorontoCollaborator
- University of TorontoOfficial
- University of TorontoSponsor investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.